Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical Company Limited (TAK) is named as the issuer in a notice reporting that Chief Human Resources Officer Nicola Greenway proposes to sell 7,348 American Depositary Shares (ADSs), with an approximate sale date of July 13, 2026 and an aggregate market value of $123,072.06. The notice states that Greenway acquired 19,754 ADSs from Takeda on July 1, 2026 through vested restricted stock unit awards. Kate Huleatt signed by power of attorney for Greenway.
Takeda Pharmaceutical Company Limited has a shareholder planning to sell American Depositary Shares (ADSs). The planned sale covers up to 4,319 ADSs of Takeda, to be executed through Interactive Brokers LLC on or after July 13, 2026 on the NYSE. The securities to be sold were received as Restricted Stock Unit awards that vested on July 1, 2026, with a separate entry showing 13,988 ADSs acquired on that date as compensation.
Takeda Pharmaceutical Company Limited submitted a notice for the proposed sale of American Depositary Shares (ADSs) under Rule 144. The notice covers up to 7,889 ADSs, to be sold through Interactive Brokers LLC on the NYSE on or after July 13, 2026, with an indicated aggregate market value of $132,148.97. It also lists activity in the prior three months, including 25,586 ADSs related to Restricted Stock Unit Awards – Vested dated July 1, 2026, categorized as compensation.
Takeda Pharmaceutical Company Limited reports a planned sale of 15,188 American Depositary Shares (ADSs) of its stock through Interactive Brokers LLC on the NYSE on July 13, 2026, with an aggregate market value of $254,398.88. The ADSs relate to previously issued equity compensation, and 143,310,556 shares of the issuer’s securities are reported as outstanding. During the prior three months, 38,982 ADSs tied to vested Restricted Stock Unit awards were sold on July 1, 2026 for compensation purposes.
Takeda Pharmaceutical Company Limited (TAK) is the issuer in a Form 144 notice listing a proposed sale for Rhonda Pacheco, identified as President, US Business Unit and US Country Head. The notice lists 18,316 American Depositary Shares (ADSs) for sale, with an approximate sale date of July 13, 2026, and an aggregate market value of $306,789.1. Interactive Brokers LLC is named as the broker. The notice lists 143,310,556 ADSs outstanding and states that Pacheco acquired 50,582 ADSs through vested restricted stock unit awards on July 1, 2026.
A holder of Takeda Pharmaceutical Company Limited American Depositary Shares (ADSs) has filed to sell up to 179,239 ADSs through Interactive Brokers LLC on the NYSE, with a stated aggregate market value of $3,002,257.72. The transaction is referenced with a date of July 13, 2026.
The ADSs relate to Restricted Stock Unit awards that vested on July 1, 2026, categorized as compensation, with 358,730 ADSs shown in connection with those vested awards. No securities sold during the past three months are listed.
A holder of Takeda Pharmaceutical Company Limited American Depositary Shares plans to sell up to 54,210 ADSs on the NYSE, through Interactive Brokers LLC, with an indicated aggregate market value of $908,019.02 as of 07/13/2026.
The securities relate to Restricted Stock Unit awards that vested on 07/01/2026, when 114,144 ADSs were acquired as compensation.
Takeda Pharmaceutical Company Limited (TAK) President and CEO Julie Kim reported 96,558 American Depositary Shares (ADSs) for sale, with an approximate sale date of July 13, 2026. The notice gives an aggregate market value of $1,617,344.29 and identifies Interactive Brokers LLC as broker. It lists 190,406 ADSs acquired from Takeda through restricted stock unit awards that vested on July 1, 2026.
Takeda Pharmaceutical Company Limited furnishes a detailed Corporate Governance Report describing how it manages its global biopharmaceutical business. The company states it complies with all principles of Japan’s Corporate Governance Code, with an 11-member Board of Directors that includes eight Independent External Directors and is chaired by an independent director. Takeda emphasizes strong oversight via an Audit and Supervisory Committee made up entirely of Independent External Directors, plus nomination and compensation committees composed solely of externals.
The report highlights shareholder structure and engagement. Foreign shareholders hold 30% or more of shares as of the end of March 2026, and the two largest trust bank shareholders each own more than 5%. Takeda describes extensive investor-relations activities, early and bilingual AGM materials, electronic voting, and regular dialogue with institutional and retail investors. It confirms no anti-takeover measures and no controlling shareholder.
Takeda stresses sustainability and stakeholder focus, including climate, nature, and product sustainability programs, and disclosures aligned with TCFD and TNFD. It describes diversity and human capital initiatives: in Japan, women account for 22.5% of managers and 4.1% of managers are non-Japanese as of March 31, 2026, while globally women hold 43% of management roles. The company outlines leadership development, digital upskilling, flexible leave and housing benefits, and a 2.92% employment rate for people with disabilities in Japan.
Takeda Pharmaceutical Company Limited completed the issuance of new shares and disposal of treasury shares on July 8, 2026 under its long-term incentive plan for group employees outside Japan. After a partial forfeiture of rights by some planned allottees, the company issued and disposed of 16,877,109 ordinary shares at 5,050 yen per share, comprising 10,780,950 new shares and 6,096,159 treasury shares, for a total value of 85,229,400,450 yen. Takeda states that the resulting changes from the previously planned figures are expected to have an immaterial impact on full-year financial results for the fiscal year ending March 31, 2027.